 |
 |
Joe Lyssikatos Principal Scientist: Discovery Chemistry |
Top Scientific Papers
- Hansen J D, Grina J, Newhouse B, Welch M, Topalov G, Littman N, Callejo M, Gloor S, Martinson, Laird E, Brandhuber B J, Vigers G, Morales T, Woessner R, Randolph N, Lyssikatos J, Olivero A. Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorganic & Medicinal Chemistry Letters 2008; 18; 4692-4695. View Abstract on PubMed
- Thomas A T, De Meese J, Le Huerou Y, Boyd S A, Romoff T T, Gonzales S S, Gunawardana I, Kaplan T, Sullivan F, Condroski K, Lyssikatos J P, Aicher T D, Ballard J, Bernat B, DeWolf W, Han M, Lemieux C, Smith D, Weiler S, Wright S K, Vigers G, Brandhuber B. Non-charged thiamine analogs a inhibitors of enzyme transketolase. Bioorganic & Medicinal Chemistry Letters 18; 509-512. View Abstract on PubMed
- Yeh, T C, Marsh V, Bernat B A, Ballard J, Cowell H, Evans R J, Parry J, Smith D, Brandhuber B J, Gross S, Marlow A, Hurley B, Lyssikatos J, Lyssikatos J, Lee P, Winkler J, Koch K, Wallace E. Biological characterization of ARRY-142886 (AZD6244), a potent highly selective mitogen-activated protein kinase ½ Inhibitor. Clinical cancer Research 2007; 13 (5): 1576-1583. View Abstract on PubMed
- Wallace E, Lyssikatos J, Blake J F, Seo J, Yang H W, Yeh T C, Perrier M, Jarski H, Marsh V, Poch G, Livingston M G, Otten J, Hingorani G, Woessner R, Lee P, Winkler J, Koch K. Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 4-(4-Bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones. Journal of Medicinal Chemistry 2006; 49(2): 441-444. View Abstract on PubMed
- Wallace E, Lyssikatos J P, Yeh T, Winkler J D, Koch K. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Current Topics in Medicinal Chemistry 2005; 5(2): 215-229. View Abstract on PubMed
- Roberts W G, Whalen P M, Soderstrom E, Moraski G, Lyssikatos J P, Wang HF, Cooper B, Baker D A, Savage D, Dalvie D, Atherton J A, Ralston S, Szewc R, Kath J C, Lin J, Soderstom C, Tkalcevic G, Cohen B D, Poallck V, Barth W, Hungerford W, Ung E. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673451. Cancer Research 2005; 65(3): 957-966. View Abstract on PubMed
- Andresen B M, Couturier B, Cronin M, D'Occhio M, Ewing M, Guinn J M, Hawkins V J, Jasys S D, LaGreca J P, Lyssikatos G, Moraski K, Ng J W, Tagoon A M, Stewart D L, Tickner J L, Tucker F J, Urban E, Vazquez L. Streamlined processes for the synthesis of a farnesyl transferase inhibitor drug candidate. Organic Process Research & Development 2004; 8: 643-650. View Abstract on PubMed
- Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, El-Deiry W S. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells, and can stabilize wild-type p53 protein. Cancer Biology and Therapy 2002; 1: 47-55. View Abstract on PubMed
- Coleman K G, Lyssikatos J P, Yang B V, Chemical Inhibitors of Cyclin-Dependent Kinases. Annual Reports in Medicinal Chemistry 1997; 32: 171-9.
- Linde RG, Lyssikatos J P, et al. Cyclic Homopentapeptides. 3. Synthetic Modifications to the Capreomycins and Tuberactinomycins: Compounds With Activity Against Methicillin-Resistant Staphylococcus Aureus and Vancomycin-resistant Enterococci, Bioorg. Med. Chem, Lett. 1997; 7(9): 1149-1152.
- Lyssikatos, J P, et al. Cyclic Homopentapeptides. 2. Synthetic of Viomycin. Bioorg. Med. Chem, Lett. 1997; 7(9): 1145-1158.
- Dirlam J P, Lyssikatos J P, et al. Cyclic Homopentapeptides. 1. Analogs of Tuberactinomycins and Capreomycin With Activity Against Vancomycin-Resistant Enterococci and Pasteurell. Bioorg. Med. Che, Lett. 1997; 7(9): 1139-1144.
- Lyssikatos J P, Bednarski M D. Synthesis of the 4,5-Diphosphonate Analog of D, L-myo-Inositol 4,5-Diphosphate. Bioorg. Med. Chem Lett. 1993; 3(4): 685-8.
- Lyssikatos J P, Bednarski M D, An Anomalous Case of Diastereoselectivity in Diels-Alder Reactions Using Chiral Dienes: Is Pi-Stacking Involved? Synlett 1990; 4: 230-3.